Why the study?
Hilotherapy was evaluated during chemotherapy infusion to prevent the onset of chemotherapy-induced peripheral neurotoxicity.
Does hilotherapy prevent the onset of chemotherapy-induced peripheral neuropathy in ovarian cancer patients?
Does hilotherapy prevent the onset of chemotherapy-induced peripheral neuropathy in ovarian cancer patients?
Hilotherapy appears well tolerated and may be effective in preventing chemotherapy-induced peripheral neuropathy in ovarian cancer patients.
Answers are grounded in this paper and cite their sources.
Hilotherapy tolerability in this case series does not support routine adoption; leaves open its role in CIPN prevention pending controlled trials.
Chemo care device is a regional cooling system that lowers the temperature of the hands and feet to reduce the flow of chemotherapy into the capillaries. We used hilotherapy during chemotherapy infusion to prevent the onset of CIPN. Updated data from 44 ovarian cancer patients treated with 6 cycle of CP show that hilotherapy was well tolerated; only two patients (4.5%) stopped hilotherapy because of cold intolerance, and only one patient (2.2%) experienced grade ≥ 2 CIPN.
No takes yet. Share an insight, caveat, or question.
Oneda et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: